ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Structural Interventional Cardiology
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1572812
Short-Term Outcomes of Transcatheter Perimembranous Ventricular Septal Defect Closure Using the Konar-Multifunctional Occluder: The Taiwanese Experience
Provisionally accepted
Lichin Liao1
Yun-Ching Fu2*
Bih-Chang Lee3Sheng-Ling Jan3Ming-Chih Lin3Chieh-Mao Chuang3Hui-Chih Hung4*- 1Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan
- 2Department of Pediatric Cardiology, Children’s Medical Center, Taichung Veterans General Hospital,, Taichung, Taiwan
- 3Department of Pediatric Cardiology, Children’s Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan
- 4Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Transcatheter device closure of perimembranous ventricular septal defect (PmVSD) using the Lifetech KONAR-MF ventricular septal defect occluder (MFO) presents a promising and effective alternative to surgical repair.This study aims to evaluate the 6-month safety and efficacy of the MFO device for PmVSD closure.We conducted a retrospective analysis of clinical data from patients who underwent percutaneous PmVSD closure using the MFO device at our institution between December 2021 and June 2024.Safety, procedural and 6-month outcomes were systematically assessed.A total of 115 patients (52.2% male) underwent transcatheter PmVSD closure. The median age was 7.6 years (interquartile range [IQR], 4.0-27.2) and weight 25.6 kg (IQR, 14.2-62.6). Median defect size by angiography was 5.7 mm (IQR, 3.8-8.3) on the left ventricle side and 3.3 mm (IQR, 2.3-4.4) on the right ventricle side. Aortic valve prolapse (AVP) was noted in 114 patients (99.1%), with preprocedural aortic regurgitation (AR) in 36 (31.3%). Median pulmonary artery pressure was 17 mmHg (IQR, 14-20); 48 (41.7%) had Qp/Qs >1.5. All procedures were successful; 33 (28.7%) used a retrograde approach. Median fluoroscopy time was 22 minutes (IQR, 15-33). Complete closure was achieved in 51.3% at 1 day, 62.6% at 1 month, 69.6% at 3 months, and 83.5% at 6 months. Transient conduction disturbances (n=4), hypotension (n=1), and femoral hematoma (n=1) were observed. No cases of endocarditis, valve injury, or complete atrioventricular block occurred.Transcatheter closure of PmVSD with the MFO demonstrated safety and efficacy during the 6-month follow-up period. Notably, the majority of defects in this cohort were small in size.
Keywords: Ventricular septal defect, Occluder, Transcatheter closure, Konar-MF Occluder, Congenital heart defect
Received: 07 Feb 2025; Accepted: 09 May 2025.
Copyright: © 2025 Liao, Fu, Lee, Jan, Lin, Chuang and Hung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yun-Ching Fu, Department of Pediatric Cardiology, Children’s Medical Center, Taichung Veterans General Hospital,, Taichung, Taiwan
Hui-Chih Hung, Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.